Bibliographies thématiques / Jing Xian yi yuan

Littérature scientifique sur le sujet « Jing Xian yi yuan »

Auteur : Grafiati
Publié le 26 juillet 2024
Mis à jour le 27 juillet 2024

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Sommaire

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Jing Xian yi yuan ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Jing Xian yi yuan"

1

Belaya, Irina. « Song of the Great Dao of the Spiritualized Source : Preliminary Study ». Voprosy Filosofii, no 5 (juillet 2024) : 178–89. http://dx.doi.org/10.21146/0042-8744-2024-5-178-189.

Texte intégral
Résumé :
The article is devoted to the study of the Song of the Great Dao of the Spiritualized Source (Ling yuan da dao ge). This is a work on Daoist “inner alchemy”, which describes the process of transforming the spirit and the breath in poetic form. The author of Ling yuan da dao ge was the Daoist nun and poetess Cao Wen-yi (1039–1115). Cao Wen-yi is the only woman-philosopher who wrote a commentary on the Dao De jing, which has survived to this day in the Daoist Canon (Dao zang). Her talents were highly appreciated by Emperor Huizong, who granted her the title “Excellent in Literary Talent” (Wen-yi zhen-ren). The goal of the study is to highlight the most important ideological and theoretical components of the Song of the Great Dao of the Spiritualized Source. As a result of the study, the cultural and historical environment of this work was reconstructed, its earlier list written in prose was identified, the dating of the full version of Ling yuan da dao ge was clarified, and its content features were revealed. The main task of the Song of the Great Dao of the Spiritualized Source is to explain the principle of simultaneous improvement of inner nature and vitality (xing ming shuang xiu). This principle became the main vector of development of Daoist psychophysiological methods, starting from the Song era. Improving the inner nature, according to Cao Wen-yi, is achieved by detaching the heart from feelings and desires. This state is called “no heart” (wu xin) and is the “true heart of the Dao”. Improving vitality is achieved through breathing exercises, which should be based on the principles of suchness (zi ran) and non-action (wu wei).
Styles APA, Harvard, Vancouver, ISO, etc.
2

Wang, Nan, Zhuonan Wang et Hongyu Zheng. « Round Heaven and Square Earth, the Unity of the Pagoda and Statues—A Study on the Geometric Proportions of the Architectural Space, Statues, and Murals in Ying Xian Fogong Si Shijia Ta 應縣佛宮寺釋迦塔 (Sakyamuni Pagoda of Fogong Temple in Ying County) ». Religions 15, no 7 (30 juin 2024) : 802. http://dx.doi.org/10.3390/rel15070802.

Texte intégral
Résumé :
In Ying Xian Fogong Si Shijia Ta 應縣佛宮寺釋迦塔 (Sakyamuni Pagoda of Fogong Temple in Ying County), Shanxi, there are statues set on each floor, and 26 exist in total, with six murals painted on the first floor. The pagoda was designed as a vertically rising Buddhist temple, and the interior space of each floor was customized for the statues. Based on previous research and through surveying and mapping of the architecture and statuary (including the murals on the first floor) combined with geometric design analysis, this paper proposes the following: First, there exists a clear geometric proportion among the interior space and statues on each floor of the pagoda. Second, clear proportional relationships also exist among the statues on each floor, and each of the 26 statues has ‘classical’ proportion rules. Third, the height of the giant Buddha statue on the first floor is the module for not only the height of the statues on each floor but also the construction of the whole pagoda such that the height of the statue on the first floor is 1/6 of the total height of the pagoda (excluding the base). And the ratio of the pagoda’s total height to the first floor’s diameter, the ratio of the total height to the top-story height under the column capital, and all the other geometric proportions are closely related to the architectural modeling. And finally, in the construction of the pagoda, statues, and murals, the scale is deduced to be 1 chi 尺 (Chinese foot) = 29.5 cm. These values give clear scale logics not only to the construction but also to the details of the statues. Accordingly, the most frequently used proportions in the architectural space, statues, and murals of the Pagoda of Fogong Temple are 2, 3:2, 5:3 (or 8:5), and 9:5, which are imbued with cultural messages, like Zhou Bi Suan Jing 周髀算經 (The Mathematical classic of the Zhou shadow-gauging instrument), Ying Zao Fa Shi 營造法式 (Treatise on Architectural Methods or State Building Standards), the ancient Chinese world view—tian yuan di fang 天圜地方 (the dome-shaped heaven and the flat, square earth) reflected from “ yuan fang tu 圓方圖 (rounded-square map)” and “fang yuan tu 方圓圖 (squared-circle map)”, ancient Chinese ideas that ”san tian liang di er yi shu 參天兩地而倚數 (‘three’ is the number of the heaven and ‘two’ is the number of the earth, and all numbers are based on them)” and “jiu wu zhi zun 九五之尊 (nine and five are the numbers of the honorable central position)”, and most probably related to the “mandala” of Esoteric Buddhism and to the Western “Golden Ratio”, which all need further research in depth.
Styles APA, Harvard, Vancouver, ISO, etc.
3

Zhao, Xiao Hong, Man Man Han, Qian Qian Yan, Yi Meng Yue, Kai Hong Ye, Yuan Yuan Zhang, Liu Teng et al. « Abstract 7052 : p53 underpins a dependence on oxidative phosphorylation in glycolysis-competent colorectal cancer ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 7052. http://dx.doi.org/10.1158/1538-7445.am2024-7052.

Texte intégral
Résumé :
Abstract The use of mitochondrial inhibitors to target oxidative phosphorylation (OXPHOS) in cancer treatment presents a challenge due to dose-limiting toxicities. Moreover, while glycolysis-deficient cancers are vulnerable to OXPHOS inhibition in preclinical models, the full extent of phenotypical and mechanistic consequences of inhibiting OXPHOS in cancers capable of glycolysis is not yet well understood. Our results presented here offer promising insights into potential therapeutic gains from combining p53 restoration strategies with OXPHOS inhibitors, even when applied to glycolysis-competent CRC cells. Treatment with mitochondrial complex I inhibitors did not cause energy stress in CRC cells capable of glycolysis. It does, however, induce DNA replication stress, apparent through an observed cell cycle arrest at the S phase, enrichment of the G2/M DNA-damage checkpoint regulation pathway, and replication fork slowdown. Intriguingly, CRC cells harboring wildtype p53 exhibited more severe replication stress than those carrying mutant p53. Furthermore, siRNA knockdown of p53 attenuates replication stress and reduces cell cycle arrest, underlining the important role of p53 in CRC cell responses to OXPHOS inhibition. Our targeted metabolomics analysis reveals that OXPHOS inhibition results in reductions in the purine nucleotides, adenine monophosphate (AMP) and guanine monophosphate (GMP), as well as the pyrimidine nucleotide, uridine monophosphate (UMP), in CRC cells, regardless of their p53 mutational status. By supplementing cell culture mediums with the purine nucleobases adenine and guanine, and the pyrimidine nucleoside uridine, we observed a partial reversal of the replication fork slowdown and reductions in cell viability. This suggests nucleotide deficiencies are involved in the induction of DNA replication stress caused by OXPHOS inhibition. The nucleotide deficiencies were associated with a decrease in the nucleobase precursor aspartate. By adding aspartate at a supraphysiological concentration, to overcome the low expression of the excitatory amino acid transporter 1 required for cellular import of aspartate, we were able to restore the levels of nucleotides. Collectively, our findings suggest broader potential cancer treatment paradigms via OXPHOS targeting, extending beyond glycolysis-deficient cancers. Our data uncovers that CRC cells, which commonly exhibit the glycolytic phenotype, are susceptible to OXPHOS inhibition, with those carrying wildtype p53 showing heightened sensitivity. Therefore, p53 status could serve as a biomarker for predicting CRC responses to OXPHOS inhibitors. Moreover, our findings suggest that combined strategies of restoring p53 function, using small molecules such as APR-246, might enable reduced dosage of OXPHOS inhibitors in CRC treatment, thereby mitigating their dose-limiting toxicities. Citation Format: Xiao Hong Zhao, Man Man Han, Qian Qian Yan, Yi Meng Yue, Kai Hong Ye, Yuan Yuan Zhang, Liu Teng, Liang Xu, Xiao Jing Shi, Ting La, Yu Chen Feng, Ran Xu, Vinod K. Narayana, David P. De Souza, Tao Liu, Mark Baker, Rick F. Thorne, Xu Dong Zhang, Song Chen, Lei Jin. p53 underpins a dependence on oxidative phosphorylation in glycolysis-competent colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7052.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Gyootag Shin. « A Comparative Study on Yi-Tian(義天)and Jing-Yuan(淨源) ». JOURNAL OF ASIAN PHILOSOPHY IN KOREA ll, no 27 (juillet 2007) : 229–59. http://dx.doi.org/10.19065/japk..27.200707.229.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Wang, Bu Hai, Cai Yue Chen, Xian Zhang, Yu Xiang Huang, Yi Chun Zeng, Lei Li, Mao Qi Wang et al. « Abstract 5091 : The early change of serum interleukin 14α levels predicts the response to anti-PD-1 therapy in cancer ». Cancer Research 82, no 12_Supplement (15 juin 2022) : 5091. http://dx.doi.org/10.1158/1538-7445.am2022-5091.

Texte intégral
Résumé :
Abstract Background: Targeting programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) has been shown improved clinical efficacy in a wide range of tumor types. We evaluated serum interleukin 14α (IL14α) as a biomarker to predict the response of anti- PD-1 therapy. Patients and methods: Thirty advanced cancer patients treated with PD-1 inhibitor were enrolled in this study. Serum levels of IL-14α were tested at baseline and after 2 cycles of treatment. Result: Among these 30 patients, the mean expression level of IL14α before treatment was 2.1±1.21, whereas the mean level of IL14α after 2 cycles was 1.99±0.82. There were no association between the expression levels of IL14α and clinical outcome. Early change of IL14α after 2-cycles of anti-PD-1 therapy was calculated as delta IL14α % change = (IL14α level after 2 cycles - IL14α level before treatment)/IL14α level before treatment*100%. Receiver operating characteristic (ROC) was analyzed to get a cutoff point of delta IL14α % change as 2.46% (Sensitivity 85.71%, Specificity 62.5%; AUC=0.7277, P=0.034). Using this cutoff to subgroup the patients, we found higher delta IL14α % change was significantly associated with superior overall response to anit-PD-1 therapy (p=0.0072) and had a better progression free survival (p=0.0039). Conclusion: Early changes of serum IL14α level may be a useful predicting factor in advanced cancer patients with anti-PD-1 therapy. Keywords: IL14α, serum biomarker, anti-PD-1 therapy response, cancer Citation Format: Bu Hai Wang, Cai Yue Chen, Xian Zhang, Yu Xiang Huang, Yi Chun Zeng, Lei Li, Mao Qi Wang, Jing Liang Guo, Qiu Xian Li, Long Shen, Juan J. Gu, Yi Chen Liang. The early change of serum interleukin 14α levels predicts the response to anti-PD-1 therapy in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5091.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Hong, Jing Han, Chern Han Yong, Hong Lee Heng, Jason Yongsheng Chan, Mai Chan Lau, Jianfeng Chen, Jing Yi Lee et al. « Abstract LT09 : Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies ». Cancer Research 84, no 8_Supplement (15 avril 2024) : LT09. http://dx.doi.org/10.1158/1538-7445.fcs2023-lt09.

Texte intégral
Résumé :
Abstract Objectives: Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify potential therapeutic targets in different subtypes of CCA through enhancer profiling. Design: Integrative multi-omics enhancer activity profiling of diverse CCA was performed. A panel of diverse CCA cell lines, and patient-derived and cell line-derived xenografts were used to study identified enriched pathways and vulnerabilities. NanoString, multiplex immunohistochemistry staining, and single-cell spatial transcriptomics were used to explore immunogenicity of diverse CCA. Results: We identified 3 distinct groups, associated with different etiologies and unique pathways. Drug inhibitors of identified pathways reduced tumor growth in in-vitro and in-vivo models. The first group (ESTRO), with mostly fluke-associated CCAs, displayed activation in estrogen signaling and were sensitive to MTOR inhibitors. Another group (OXPHO), with mostly BAP1 and IDH-mutant CCAs, displayed activated oxidative phosphorylation pathways, and were sensitive oxidative phosphorylation inhibitors. Immune-related pathways were activated in the final group (IMMUN), made up of an immunogenic CCA subtype and CCA with aristolochic acid (AA) mutational signatures. Intra-tumor differences in AA mutation load were correlated to intra-tumor variation of different immune cell populations. Conclusion: Our study elucidates the mechanisms underlying enhancer dysregulation and deepens understanding of different tumorigenesis processes in distinct CCA subtypes, with potential significant therapeutics and clinical benefits. Citation Format: Jing Han Hong, Chern Han Yong, Hong Lee Heng, Jason Yongsheng Chan, Mai Chan Lau, Jianfeng Chen, Jing Yi Lee, Abner Herbert Lim, Zhimei Li, Peiyong Guan, Pek Lim Chu, Sheng Rong Ng, Xiaosai Yao, Peili Wang, Rong Xiao, Xian Zeng, Yichen Sun, Wei Liu, Joanna Koh, Felicia Yu Ting Wee, Jeffrey Chun Tatt Lim, Cedric Chuan Young Ng, Xiu Yi Kwek, Poramate Klanrit, Yaojun Zhang, Jiaming Lai, David Wai Meng Tai, Chawalit Pairojkul, Simona Dima, Irinel Popescu, Sen-Yung Hsieh, Ming-Chin Yu, Joe Yeong, Sarinya Kongpetch, Apinya Jusakul, Watcharin Loilome, Patrick Tan, Jing Tan, Bin Tean Teh. Integrative Multi-Omics Enhancer Activity Profiling Identifies Therapeutic Vulnerabilities in Cholangiocarcinoma of Different Etiologies [abstract]. In: Proceedings of Frontiers in Cancer Science; 2023 Nov 6-8; Singapore. Philadelphia (PA): AACR; Cancer Res 2024;84(8_Suppl):Abstract nr LT09.
Styles APA, Harvard, Vancouver, ISO, etc.
7

YoungHo Jeong. « A Comparative Research of Jing-Hua-Yuan(鏡花緣) and Di-Yi-Qi-Yan(第一奇諺) ». Journal of the research of chinese novels ll, no 26 (septembre 2007) : 271–94. http://dx.doi.org/10.17004/jrcn.2007..26.015.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Zhu, Xiu-Zhi, Yi-Fan Zhou, Yun-Yi Wang, Xiao-Hong Ding, Xi Jin, Zhi-Ming Shao, Yi-Zhou Jiang et Zhong-Hua Wang. « Abstract PO1-15-08 : Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy ». Cancer Research 84, no 9_Supplement (2 mai 2024) : PO1–15–08—PO1–15–08. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-15-08.

Texte intégral
Résumé :
Abstract Background: While primary triple-negative breast cancer (TNBC) garners significant research attention, the genomic alterations that occur in metastasis remain insufficiently understood, especially within Asian populations. Furthermore, the genomic information obtained from the primary tumor inadequately guides metastatic cancer treatment, highlighting the critical need for in-depth investigations into metastatic TNBC. Methods: We constructed the largest cohort of TNBC metastases (n = 296) among advanced TNBC patients treated at Fudan University Shanghai Cancer Center (FUSCC) between October 2018 and December 2020. Comprehensive DNA sequencing was conducted on the collected metastatic samples to analyze genomic alterations associated with treatment response. The underlying mechanisms of specific biomarkers were also explored. Results: We presented the genomic landscape of 296 TNBC metastases, encompassing mutant genes, mutation sites and copy number variations. Through multidimensional analysis, significant disparities in TNBC were observed between Western and Asian populations, primary and metastatic tumors, as well as different metastatic sites. Notably, our findings underscore the importance of sequencing TNBC metastases to guide precision therapy, which was associated with longer progression-free survival compared to physician-chosen treatments, shedding light on the pivotal clinical value of genomic studies in metastatic settings. Furthermore, efficacy analysis suggested that PKD1 mutations enriched in metastases mediated resistance to immunotherapy. These findings were further validated through three clinical trials (NCT03805399, NCT04129996, and NCT04395989). Mechanistic studies unveiled the involvement of PKD1 in TNBC immune evasion by upregulating CCL2, thereby facilitating the recruitment of M2-type tumor-associated macrophages. Conclusion: Our study emphasizes the critical significance and necessity of genomic profiling of metastases in guiding precision therapy for TNBC. Moreover, our findings reveal PKD1 as a novel and promising biomarker for immunotherapy. Citation Format: Xiu-Zhi Zhu, Yi-Fan Zhou, Yun-Yi Wang, Xiao-Hong Ding, Xi Jin, Zhi-Ming Shao, Yi-Zhou Jiang, Zhong-Hua Wang. Genomic characterization of triple-negative breast cancer metastases reveals PKD1 as a novel biomarker for immunotherapy [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-15-08.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Chan, Jason Yongsheng, Jui Wan Loh, Jing Quan Lim, Herty Liany, Elizabeth Chun Yong Lee, Jing Yi Lee, Bavani Kannan et al. « Abstract 4458 : Single cell landscape of multicentric Castleman disease in identical twins ». Cancer Research 83, no 7_Supplement (4 avril 2023) : 4458. http://dx.doi.org/10.1158/1538-7445.am2023-4458.

Texte intégral
Résumé :
Abstract Idiopathic Multicentric Castleman Disease (iMCD) is a rare IL-6-driven hematological disorder characterized by systemic lymphadenopathy, elevated immunoglobulin levels, and prominent plasmacytosis in the bone marrow and lymph nodes. An unusual occurrence of iMCD in identical twins provided a unique opportunity to answer genetic and molecular features of this disease, including the cell-of-origin of IL-6 signals, and the immune milieu within affected lymphoid organs and in circulation. Germline whole genome sequencing of the affected twins identified pathogenic homozygous mutations of NCOA4 c.G1322A and monoallelic mutations of TRAF3 c.G1504A - both genes recently implicated in IL-6 signaling and B-cell regulation. Their unaffected sister was heterozygous mutant for NCOA4 and homozygous wildtype for TRAF3 loci. Via single cell sequencing of 63,519 cells from bone marrow, lymph node, and peripheral blood mononuclear cells, we identified nodal endothelial cells and fibroblastic reticular cells (FRC) as the source of IL-6 signals. The latter are composed of mainly T-cell zone FRCs (CCL19+/CCL21+/IL7+/PDPN+/MADCAM1-) and a minor population of follicular dendritic cells (FDCs) (CD21+/CD35+/CXCL13+). An “inflammatory” peripheral monocytosis enriched for the expression of S100A family genes was evident in both twins, as well as a group of monocytes expressing cytotoxic gene signatures in the affected twin with milder clinical manifestations. Their unaffected sister mainly carried monocytes enriched for expression of major histocompatibility complex (MHC) class II genes. In conclusion, we provided evidence of a genetic cause of iMCD, identified the putative cell-of-origin of IL-6 signals in this rare disease, and described a distinct monocytic immune response phenotype. Citation Format: Jason Yongsheng Chan, Jui Wan Loh, Jing Quan Lim, Herty Liany, Elizabeth Chun Yong Lee, Jing Yi Lee, Bavani Kannan, Boon Yee Lim, Kerry Lim, Jeslin Chian Hung Ha, Cedric Chuan-Young Ng, Tun Kiat Ko, Dachuan Huang, Dominique Yuan Bin Seow, Chee Leong Cheng, Sock Hoai Chan, Joanne Ngeow, Bin Tean Teh, Soon Thye Lim, Choon Kiat Ong. Single cell landscape of multicentric Castleman disease in identical twins. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4458.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Zhu, Xiu-Zhi, Xi Jin, Hu-Yun-Long Zhang, Xiyu Liu, Yi-Fan Zhou, Yi-Yu Chen, Tong Fu et al. « Abstract PO1-15-07 : Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer : a sub-study of the MULAN umbrella trial ». Cancer Research 84, no 9_Supplement (2 mai 2024) : PO1–15–07—PO1–15–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-15-07.

Texte intégral
Résumé :
Abstract Background: The standard approach of using one-size-fits-all endocrine therapy for hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancers has faced significant challenges due to variations in treatment response among individuals. Consequently, there is still an urgent need to understand the molecular biology of HR+/HER2- breast cancer and explore precision treatment strategy. Methods: We established a multiomics cohort (n = 351), multicenter real-world clinical cohorts (n = 643), a prospective clinical cohort (MULAN trial), and a drug-testing platform containing patient-derived organoids (n = 126) and patient-derived tumor fragments (n = 49) of HR+/HER2- breast cancers. Integrating "bench" and “bedside” data, we conducted comprehensive preclinical and clinical translational research on precision strategies in HR+/HER2- breast cancer. Results: We implemented a comprehensive classification system for HR+/HER2- breast cancer, comprising four distinct subtypes. We further demonstrated the efficacy and mechanisms of subtyping-directed precision treatment strategies through clinical cohort studies, omics analysis and functional assays: endocrine therapy alone for the canonical luminal subtype; the addition of CDK4/6 inhibitor and PARP inhibitor for the proliferative subtype; the immunotherapy for the immunogenic subtype; and tyrosine kinase inhibitors for the receptor tyrosine kinase-driven subtype. Using clinically applicable subtyping methods, we validated that matched precision treatment strategies outperformed unmatched approaches in a real-world cohort, almost doubling the median progression-free survival time for patients with refractory advanced HR+/HER2- breast cancer (9.83 months [95% CI, 5.74-13.93] vs 4.77 months [95% CI, 3.35-6.18]; hazard ratio 0.64 [95% CI, 0.41-0.99]). Importantly, the first-stage analysis of the MULAN phase II umbrella clinical trial (NCT04355858) verified the higher objective response rate (88.9%, 95%CI: 51.7%-99.7%) of the subtyping-directed precision treatment. Conclusion: Our study emphasizes the superiority of subtyping-directed precision treatment strategies for HR+/HER2- breast cancer, refines traditional “one-size-fits-all” therapy, and facilitates the translation of precision treatment strategies from bench to bedside. Overall study design Part 1 Subtype Molecular Characteristics: Molecular features of the four subtypes of HR+/HER2- breast cancer. Part 2 Multidimensional Efficacy Validation: Integrating data from a multiomics cohort, real-world study, drug testing platform and prospective clinical research to validate the subtyping-directed precision treatment strategy in HR+/HER2- breast cancer. Part 3 Subtyping-directed Precision Treatment Strategy: Integrating clinical cohort studies, omics analysis and functional assays revealed the heterogeneity of treatment response in HR+/HER2- breast cancer, and proposed a subtyping-directed precision treatment strategy. CIN, chromosomal instability; RTK, receptor tyrosine kinase; CNA, copy-number alteration; ER, estrogen receptor; HR, hormone receptor; HER2, human epidermal growth factor receptor 2. Citation Format: Xiu-Zhi Zhu, Xi Jin, Hu-Yun-Long Zhang, Xiyu Liu, Yi-Fan Zhou, Yi-Yu Chen, Tong Fu, Ming-Liang Jin, Ya-Xin Zhao, Yi-Fan Xie, Ruo-Xi Wang, Zhong-Hua Wang, Lei Fan, Yi-Zhou Jiang, Zhi-Ming Shao. Subtyping-directed precision treatment refines traditional one-size-fits-all therapy in HR+/HER2- breast cancer: a sub-study of the MULAN umbrella trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-15-07.
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources

Thèses sur le sujet "Jing Xian yi yuan"

1

Ma, Yihua. « Zhong yi yao zhi liao tong jing (yuan fa xing tong jing) de wen xian yan jiu / ». click here to view the abstract and table of contents, 2006. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b1998747xa.pdf.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Guan, Qiyun. « Cong xian xiang xue jiao du tan tao da xue xue sheng ling xiu xiao yuan ke wai huo dong jing li de yi yi = The out-of-class experiences of university student leaders : a phenomenological approach / ». click here to view the abstract and table of contents, 2002. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b17563380a.pdf.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Li, Wen. « Shui shang fu sheng : yi ge bian yuan qun ti zai xian dai Zhongguo Guangdong Xijiang de xing cheng / ». View abstract or full-text, 2006. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202006%20LIW.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Li, Fuli. « A stress and coping perspective on creativity : a reward for creativity policy as a stressor in organizations = Cong ya li he ying dui de jiao du li jie chuang xin : zu zhi chuang xin jiang li zheng ce zuo wei yi zhong ya li yuan / Li Fuli ». access full-text access abstract and table of contents, 2009. http://libweb.cityu.edu.hk/cgi-bin/ezdb/thesis.pl?phd-mgt-b30082468f.pdf.

Texte intégral
Résumé :
Thesis (Ph.D.)--City University of Hong Kong, 2009.
"Submitted to Department of Management in partial fulfillment of the requirements for the degree of Doctor of Philosophy." Includes bibliographical references (leaves 158-173)
Styles APA, Harvard, Vancouver, ISO, etc.
5

Zhang, Jian. « Ke xue she tuan zai jin dai Zhongguo de ming yun yi Zhongguo ke xue she wei zhong xin = The science association and the change of society in modern China : a study on The science society of China / ». Jinan Shi : Shandong jiao yu chu ban she, 2005. http://catalog.hathitrust.org/api/volumes/oclc/64694546.html.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Wang, Lianghe. « Shi guan de chong tu yu zhu liu de jing zhu : Xianggang ba, jiu shi nian dai shi tan de liu pai fen zheng--yi "Zhong Weimin xian xiang" ying zhao = The clash of poetic views and striving to be the centre : an exploration of the conflict between poetic schools in the 1980s and 90s in Hong Kong in the light of the "Chung Wai Man phenomenon" / ». click here to view the abstract and table of contents, 2001. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b17040474a.pdf.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Chen, Meng-ching, et 陳孟卿. « A Study on Ciyun Zunshi''s "Wang Sheng Jing Tu Chan Yuan Yi" ». Thesis, 2012. http://ndltd.ncl.edu.tw/handle/48335999460561139141.

Texte intégral
Résumé :
碩士
南華大學
宗教學研究所
100
Ciyun Zunshi (964 ~ 1032) lived in Tiantai Sect in Song Dynasty, during which Pure-land Sect was very popular with many sects of Buddhism seeking their destiny of returning to the pure land. In Song Dynasty, Tiantai Sect advocated and practiced the doctrines of Buddha. Zunshi was determined to preach the way of Tiantai by practicing the way of Buddha. In his entire life, he had always been preaching, repenting in system and ritual and reciting Buddhism sutras, especially for the importance of the methods of redemption. The book “Wang Sheng Jing Tu Chan Yuan Yi” written by him was a convergence of ideas of Pure-land and Tiantai which intelligently combined and applied the doctrines of two sects, presenting the practice of religious life. 　 　　“Wang Sheng Jing Tu Chan Yuan Yi” was a collection of redemption methods compiled by Zunshi from Amitayus Sutra and other Mahayana Sutras that honor the Pure-land. It centers on the structure of Tiantai Sect and then absorbs the ideas of Pure-land, which makes it a redemption rite featuring Tiantai Sect, Pure-land ideas and the belief of redemption. The redemption rites book was produced under the influence of convergence of sects in Song Dynasty. It featured both Tiantai and Pure-land ideas, casting profound influence to the practicers of Pure-land and Tiantai. Afterwards, redemption rites become one of the most important rites in Buddhism culture. Therefore, Zunshi’s “Wang Sheng Jing Tu Chan Yuan Yi” is not only a book reflecting Buddhism ideas, but also a guideline to the rite of redemption. 　 　　This thesis consists of 6 chapters. The first chapter is introduction. The second chapter introduces Ciyun Zunshi’s life and era background. The third chapter is about the causes of redemption rites in “Wang Sheng Jing Tu Chan Yuan Yi”. The fourth chapter introduces religious meaning and ritual characteristics of “Wang Sheng Jing Tu Chan Yuan Yi”. The fifth chapter discusses the impact of “Wang Sheng Jing Tu Chan Yuan Yi” Song and afterward cultures. The last chapter is conclusion. 　 　　The first chapter is introduction which mainly elaborates the motive and purpose of this thesis and the comments over the present studies and theses related to Ciyun Zunshi’s life, ideas and methods of redemption, and discusses the research scope and thesis structure. 　 　　The second chapter mainly introduces Ciyun Zunshi’s era background and life, his works and his practices of Buddhism ideas. The third chapter is about the causes of redemption rites in “Wang Sheng Jing Tu Chan Yuan Yi”, and the formation background and era of the book as well as the structure of ritual redemption. 　 　　The fourth chapter analyzes the content and religious features of “Wang Sheng Jing Tu Chan Yuan Yi” to probe into the characteristics of the Redemption of Pure-land, such as Sin Purgatory through redemption, causes of Samadhi achievements and pure-land of afterlife and the Convergence of the ideas of Tiantai Sect and Pure-land as well as other religious features. 　 　　The fifth chapter illustrates the Buddhism culture influence of “Wang Sheng Jing Tu Chan Yuan Yi” on Song Dynasty and the latter Buddhism Redemption culture. In the end, the sixth chapter concludes the research results, summing up the previous 5 chapters on key ideas and redemption rites of “Wang Sheng Jing Tu Chan Yuan Yi” as well as its Buddhism significance, research limitations and future prospects.
Styles APA, Harvard, Vancouver, ISO, etc.

Livres sur le sujet "Jing Xian yi yuan"

1

"Jing Xian yi yuan zhi" bian zuan wei yuan hui. Jing Xian yi yuan zhi, 1940-2007. [Jing Xian : Jing Xian yi yuan, 2008.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Nyū Hausu Shuppan Kabushiki Kaisha., dir. Xian dai Ri shi ting yuan : Zao jing yi shu jing xuan. Zhonghe Shi [Taiwan] : Rui sheng wen hua shi ye gu fen you xian gong si, 2002.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Xiao, Mengxia. "Ti yong yi yuan, xian wei wu jian" Cheng Yichuan de li yi ben si xiang yan jiu : Yi "Cheng shi Yi zhuan" wei zhong xin. Chengdu Shi : Sichuan da xue chu ban she, 2017.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Zhao, Wen, 1963- compiler, author, dir. Ling yuan jia ke : Li Zhongyu xian sheng yi dao chuan xin lu. Shenyang Shi : Liaoning ke xue ji shu chu ban she, 2016.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Wang, Tiemei. Xiao fei xian jing : 180 zhao jiao ni bu hua yuan wang qian. Tianjin : Tian jin ke xue ji shu chu ban she, 2011.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Hayashi, Hideichi. Xiao jing shu yi fu yuan yan jiu. Wuhan Shi : Chong wen shu ju, 2016.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Xin yi Dizang pu pu ben yuan jing. Taibei Shi : San min shu ju, 2005.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Zhong yang she hui zhu yi xue yuan Li lun xue xi zhong xin zu. Hua chu zui da de tong xin yuan : Xi jin ping zhong yang tong zhan gong zuo hui yi zhong yao jiang hua jing shen xue xi jiang zuo. Beijing : Zhong gong zhong yang dang xiao chu ban she, 2015.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Shen, Hanguang. Congshan ji : Shi yi juan (shi xuan ba juan wen ji san juan) fu lu er juan (nian pu chuan zhi yi juan xiang xian lu yi juan) ; Jing yuan xiao yu : yi juan ; Jing yuan jin yu : yi juan. Shanghai : Shanghai gu ji chu ban she, 2009.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Long, Jianchun. He tu Luo shu xiang li jie du : Shen mi wen hua ben yuan. Taibei Shi : Lan Tai chu ban she, 2012.

Trouver le texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Plus de sources
Vous pouvez également être intéressé par les bibliographies sur le sujet « Jing Xian yi yuan » pour d’autres types de sources :
Articles de revues Livres
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie